Zoetis’ (ZTS) Hold Rating Reaffirmed at BMO Capital Markets
Zoetis Inc. (NYSE:ZTS)‘s stock had its “hold” rating restated by stock analysts at BMO Capital Markets in a note issued to investors on Thursday. They presently have a $65.00 price objective on the stock. BMO Capital Markets’ target price suggests a potential upside of 1.85% from the stock’s current price.
Several other research analysts also recently commented on ZTS. BidaskClub downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. Finally, Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the stock. Zoetis presently has an average rating of “Buy” and a consensus price target of $65.76.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.03. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.52 EPS.
TRADEMARK VIOLATION WARNING: “Zoetis’ (ZTS) Hold Rating Reaffirmed at BMO Capital Markets” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/zoetis-zts-hold-rating-reaffirmed-at-bmo-capital-markets.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after buying an additional 1,412,829 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after purchasing an additional 910,265 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after purchasing an additional 3,695,449 shares in the last quarter. Clearbridge Investments LLC increased its holdings in shares of Zoetis by 4.2% during the 1st quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock valued at $493,921,000 after purchasing an additional 373,568 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Zoetis by 7.2% during the 2nd quarter. American Century Companies Inc. now owns 6,207,974 shares of the company’s stock valued at $387,253,000 after purchasing an additional 417,455 shares in the last quarter. 93.04% of the stock is owned by institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.